DMA Diamedica Therapeutics

DiaMedica Inc. (TSX VENTURE:DMA), a drug discovery and development company
focused on novel treatments for Type 2 diabetes, today announces that it has
enrolled the final patient in the phase II proof of concept clinical trial of
DM-83.


Mr. Rick Pauls, DiaMedica's Interim President and CEO, said the twenty patient
single-blind trial will demonstrate DM-83's level of effectiveness in
controlling blood glucose and insulin levels in Type 2 diabetic patients after
they have consumed a standard meal. Changes in insulin and glucose levels are
the study's primary endpoints. Each patient will test both the effects of DM-83
as well as a placebo and therefore serve as their own control in this crossover
study. All patients have now completed treatment and last patient is expect to
complete the study in the second quarter with results to be analyzed and
released shortly thereafter. The results of this trial will be used to optimize
the design of the next stage of clinical development for DM-83.


"One of the key strengths of the Company's business platform is our ability to
move drug candidates into clinical trials more quickly than traditional drug
development", stated Mr. Pauls. "This is because we are using compounds that
have already been approved for use in humans. The fact that DM-83 is a
combination of two such compounds has allowed us to move it into a phase II
trial in an expedient manner".


The inability to use insulin produced by the pancreas is a significant problem
for people who suffer from Type 2 diabetes. This is demonstrated by the fact
that many Type 2 diabetics have high levels of both glucose and insulin
circulating in their bloodstream. DiaMedica believes that restoring insulin
sensitivity and allowing the body to use its own naturally produced insulin is
the key to combating this illness. Preclinical animal studies have demonstrated
that DM-83 is able to restore insulin sensitivity to near pre-diabetic levels
and has been shown to be safe.


Diabetes is a widespread and rapidly growing disease, affecting over 180 million
people world wide with over 90% of diabetics being diagnosed with the Type 2
form of the disease. According to the World Health Organization this number is
expected to double during the next 15 years while the American Diabetes
Association has estimated the annual economic cost in 2007 to the United States
to be $174 billion. Global sales of oral diabetes drugs total $6 billion today
and are expected to climb to $11 billion by 2011.


About DM-83

DM-83 has demonstrated the ability to restore insulin sensitivity in an animal
model of diabetes. The product is a novel combination of two known compounds
with well established safety profiles that are used to treat other unrelated
human conditions, one of which is used to improve cardiovascular conditions.
Studies have shown that neither compound is able to restore insulin sensitivity
on its own, while combining the two results in a synergistic effect that
restores insulin sensitivity to pre-diabetic levels.


About DiaMedica

DiaMedica is developing novel treatments for various stages of type 2 diabetes.
The Company recently completed a phase II clinical trial with its lead product
DM-71 which demonstrated the ability to reduce HbA1c levels in man. The Company
has two other drugs in its clinical pipeline, DM-83 and DM-99, which are moving
through phase II proof of concept clinical studies.


Caution Regarding Forward-Looking Information 

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: DiaMedica's early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in DiaMedica's filings with Canadian securities regulatory
authorities, as well as DiaMedica's ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release, as well as under the
heading "Risk Factors" contained in DiaMedica's final long-form prospectus dated
March 12, 2007. DiaMedica cautions that the foregoing list of important factors
that may affect future results is not exhaustive. When relying on DiaMedica's
forward-looking statements to make decisions with respect to DiaMedica,
investors and others should carefully consider the foregoing factors and other
uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, DiaMedica
cannot provide assurance that actual results will be consistent with these
forward-looking statements. DiaMedica undertakes no obligation to update or
revise any forward-looking statement.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024